Journal of Alzheimers Disease & Parkinsonism
Open Access

Yannick Marchalant

NICN, UMR , Université de la Méditerranée, Marseille, France

Biography

 

Dr. Yannick Marchalant obtained his Ph.D. from the University of Caen, France in 2004. After graduating, he moved to the University of Arizona and then onto The Ohio State University as a post-doctoral researcher for 4 years. He then became a research assistant professor in 2008 at The Ohio State University for 2 years. He moved back to Europe for 4 years in Aix-Marseille University, France and joined​ the Psychology Department at Central Michigan University in the fall of 2014 as an assistant professor. He has been working for 15 years on neurodegenerative disease, in particular Alz​heimer's disease, and has studied notably the role of neuroinflammation in brain aging as well as the influence of the endocannabinoid system on the regulation of inflammatory processes in the context of Alzheimer's disease.

Research Interest

I have been actively working for the past 15 years on different aspects of normal and pathological ageing (behavioural and biochemical approaches), particularly in Alzheimer's disease (AD, more precisely on the cholinergic hypothesis, neuroinflammation processes and their implication), leading to several innovative publications in the field. My work has drawn attention to the role of the endocannabinoid system in the control of neuroinflammation associated with AD. 

Most recently, I have been particularly interested in:

• The effect of WIN-55, 212-2, an agonist of the GPCR endocannabinoids type 1 and 2, for its anti-inflammatory properties in a mouse model of AD (5xFAD).
• The role of​ the deletion of MT5-MMP in the progression of AD in 5xFAD mice.

 

In the few years, I would like to continue my research on the role of inflammation and its implication on learning and memory in normal and pathological aging (AD). In parallel, I want to study more closely the exact role on inflammation in the onset/progression of AD. Indeed, despite evidence in diagnosed patients and post-mortem tissues, neuroinflammation has not been definitely demonstrated as major risk factor in AD.